Vaxcyte (PCVX): Assessing a Discounted Valuation After a Volatile Year in the Share Price [Yahoo! Finance]
Vaxcyte, Inc. (PCVX)
Company Research
Source: Yahoo! Finance
See our latest analysis for Vaxcyte. Against that backdrop, Vaxcyte's recent pullback, including an 8.6% 1 month share price return and 49.3% 1 year total shareholder return decline, sits alongside a powerful 43.6% 3 month share price rebound that suggests sentiment is tentatively rebuilding. If this kind of volatility has your attention, it could be a good moment to explore other innovative names in healthcare stocks for fresh ideas beyond a single biotech story. With shares still trading well below analyst targets despite no revenue and widening losses, the real debate now is simple: is Vaxcyte an underappreciated growth story, or has the market already priced in its vaccine pipeline potential? At a last close of $44.50, Vaxcyte trades at roughly 2x price to book, a level that looks restrained against typical biotech valuations. The price to book ratio compares the company's market value to its net assets on the balance sheet, a useful yardstick for pre revenue biotechs w
Show less
Read more
Impact Snapshot
Event Time:
PCVX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PCVX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PCVX alerts
High impacting Vaxcyte, Inc. news events
Weekly update
A roundup of the hottest topics
PCVX
News
- Vaxcyte to Present at the Guggenheim Emerging Outlook: Biotech SummitGlobeNewswire
- Vaxcyte Funding And Late-Stage Trials Put Valuation In Focus [Yahoo! Finance]Yahoo! Finance
- Vaxcyte Announces Closing of $632.5 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares [Yahoo! Finance]Yahoo! Finance
- Vaxcyte Announces Closing of $632.5 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional SharesGlobeNewswire
- Vaxcyte (NASDAQ:PCVX) had its "buy" rating reaffirmed by analysts at Guggenheim. They now have a $116.00 price target on the stock.MarketBeat
PCVX
Earnings
- 11/4/25 - Miss
PCVX
Sec Filings
- 2/2/26 - Form 8-K
- 1/30/26 - Form 424B5
- 1/29/26 - Form 424B5
- PCVX's page on the SEC website